PPARA and hypertriglyceridemia: In order to identify the potential active structure via virtual screening, molecular docking studies were performed against PPARα in comparison with lanifibranor 5 and fenofibrate (positive control), which indicated potential for the treatment of severe hypertriglyceridemia and mixed dyslipidemia in patients who have not responded to nonpharmacological therapies.